ATP结合盒转运体A1基因变异与冠心病的研究进展

基础医学与临床 ›› 2012, Vol. 32 ›› Issue (9): 1107-1110.

ATP结合盒转运体A1基因变异与冠心病的研究进展

彭洁¹,郭媛²

1. 山东大学齐鲁医院心血管内科
2. 山东大学齐鲁医院

收稿日期:2011-08-18 修回日期:2011-11-29 出版日期:2012-09-05 发布日期:2012-08-28
通讯作者: 郭媛 E-mail:guoyuan_cn@163.com
基金资助:
山东省自然科学基金

Research Progress of ATP-binding cassette transporter A1 Genovariation Association with Coronary Artery Disease

Received:2011-08-18 Revised:2011-11-29 Online:2012-09-05 Published:2012-08-28

摘要/Abstract

摘要： 摘要：脂质代谢异常是冠心病的发病机制之一，ATP结合盒转运子A1（ATP-binding cassette transporter A1, ABCA1）在胆固醇的逆向转运（reverse cholesterol transport, RLT）及高密度脂蛋白（high density lipoprotein，HDL）生成中起重要作用。ABCA1基因变异可引起脂质代谢紊乱，促进动脉粥样硬化及冠心病的发生发展。本文就近年来对ABCA1基因变异与冠心病关联性及其参与冠心病发病机制方面的研究做一简述。

关键词: ATP结合盒转运体A1, 高密度脂蛋白, 基因多态性, 冠心病

Abstract: Abstract: Abnormal lipid metabolism plays an important role in the pathogenesis of coronary artery disease (CAD), ATP-binding cassette transporter A1 (ABCA1) is the rate limiting step in the reverse cholesterol transport(RLT) and high density lipoprotein(HDL) production. ABCA1 genovariation can cause abnormal lipid metabolism, promoting the development of atherosclerosis and CAD. This paper is about the study progress of ABCA1 genovariation and its effect on the pathogenesis of CAD.framework、genovariation and clinical application with CAD.

Key words: ATP-binding cassette transporter A1, high density lipoprotein, gene polymorphism, coronary artery disease

彭洁郭媛. ATP结合盒转运体A1基因变异与冠心病的研究进展[J]. 基础医学与临床, 2012, 32(9): 1107-1110.

参考文献

参考文献 [1]罗丹. AT P 结合框转运子A1 的结构、功能及调控的研究进展[J]. 国外医学临床生物化学与检验学分册, 2003, 24(5)252-253. [2] Jiang Z, Zhou R, Xu C, et al. Genetic variation of the ATP-binding cassette transporter A1 and susceptibility to coronary heart disease[J]. Mol Genet Metab,2011,103(1):81-88. [3] Doosti M, Najafi M, Reza J Z, et al. The role of ATP-binding-cassette-transporter-A1 (ABCA1) gene polymorphism on coronary artery disease risk[J]. Transl Res,2010,155(4):185-190. [4] Rejeb J, Omezzine A, Rebhi L, et al. Associations between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and coronary artery disease in a Tunisian population[J]. Arch Cardiovasc Dis,2010,103(10):530-537. [5] Ma X Y, Liu J P, Song Z Y. Associations of the ATP-binding cassette transporter A1 R219K polymorphism with HDL-C level and coronary artery disease risk: a meta-analysis[J]. Atherosclerosis,2011,215(2):428-434. [6] Nebel A, Croucher P J, El M N, et al. Common coding polymorphisms in the ABCA1 gene and risk of early-onset coronary heart disease in northern Germany[J]. Atherosclerosis,2007,193(2):458-460. [7] Kyriakou T, Hodgkinson C, Pontefract D E, et al. Genotypic effect of the -565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2005,25(2):418-423. [8] Martin M, Gonzalez P, Reguero J J, et al. ABCA1 polymorphisms and prognosis after myocardial infarction in young patients[J]. Int J Cardiol,2006,110(2):267-268. [9] Jensen M K, Pai J K, Mukamal K J, et al. Common genetic variation in the ATP-binding cassette transporter A1, plasma lipids, and risk of coronary heart disease[J]. Atherosclerosis,2007,195(1):e172-e180. [10] Cao X L, Yin R X, Wu D F, et al. Genetic variant of V825I in the ATP-binding cassette transporter A1 gene and serum lipid levels in the Guangxi Bai Ku Yao and Han populations[J]. Lipids Health Dis,2011,10:14. [11] Catakoglu A B, Duman B S, Kurtoglu H, et al. Common variants in the ATP-binding cassette transporter 1 gene with decreased HDL-cholesterol levels and coronary artery disease[J]. Arch Med Res,2008,39(8):735-742. [12] Liu L, Guo Z G, Wang Q G, et al. [Significance of -191G/C single nucleotide polymorphisms in the promoter region of ATP-binding cassette transporter gene in coronary artery disease][J]. Di Yi Jun Yi Da Xue Xue Bao,2005,25(6):660-662, 666. [13] Rhyne J, Mantaring M M, Gardner D F, et al. Multiple splice defects in ABCA1 cause low HDL-C in a family with hypoalphalipoproteinemia and premature coronary disease[J]. BMC Med Genet,2009,10:1. [14] Tabet F, Remaley A T, Segaliny A I, et al. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro[J]. Arterioscler Thromb Vasc Biol,2010,30(2):246-252. [15] Moreno P R, Sanz J, Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport[J]. J Am Coll Cardiol,2009,53(25):2315-2323. [16] Lee J, Park Y, Koo S I. ATP-binding cassette transporter A1 and HDL metabolism: effects of fatty acids[J]. J Nutr Biochem,2011. [17] Demina E P, Miroshnikova V V, Rodygina T I, et al. [ABCA1 gene expression in peripheral blood lymphocytes and macrophages in patients with atherosclerosis][J]. Mol Biol (Mosk),2011,45(2):289-293. [18] Murphy A J, Woollard K J, Suhartoyo A, et al. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation[J]. Arterioscler Thromb Vasc Biol,2011,31(6):1333-1341. [19] Yin K, Liao D F, Tang C K. ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport[J]. Mol Med,2010,16(9-10):438-449. [20] Zhu X, Owen J S, Wilson M D, et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol[J]. J Lipid Res,2010,51(11):3196-3206. [21] Getz G S, Wool G D, Reardon C A. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders[J]. Curr Pharm Des,2010,16(28):3173-3184. [22] Genvigir F D, Rodrigues A C, Cerda A, et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells[J]. Pharmacogenomics,2010,11(9):1235-1246. [23] Kobayashi M, Gouda K, Chisaki I, et al. Regulation mechanism of ABCA1 expression by statins in hepatocytes[J]. Eur J Pharmacol,2011,662(1-3):9-14.